Brian Rini, MD, is leading a study launched by the National Cancer Institute (NCI) that will closely monitor cancer patients who acquire COVID-19 with the goal of providing highly detailed data to guide future care.

Researchers at Vanderbilt University Medical Center played a key role in the development of remdesivir, the first drug approved by the U.S. Food and Drug Administration for the treatment of COVID-19.

Vanderbilt University Medical Center, in collaboration with the University of Colorado and Beth Israel Deaconess Medical Center in Boston, is leading one of the first “telemedicine” clinical trials to test a potential treatment for COVID-19.

AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center and optimized by AstraZeneca.

Though the COVID-19 pandemic halted in-person patient visits at Undiagnosed Diseases Network (UDN) sites, including Vanderbilt University Medical Center’s, since March, groundbreaking behind-the-scenes work continues.

A consortium of 17 cancer centers in the United States, including Vanderbilt-Ingram Cancer Center, have come together to better understand the consequences of the COVID-19 pandemic in delaying cancer detection, care and prevention.

Until it was eclipsed by New York in mid-April, the state of Washington had the highest absolute number of COVID-19 cases in the United States.